IN01

DB16434ExperimentalVaccines

The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria . These cultures contain EGF-4-EGF with the cholera toxin B-subunit domain... Administration of the vaccine stimulates the production of anti-epidermal growth factor (anti-EGF) neutralizing antibodies.

Code names: IN01

What you can answer from here — as of March 06, 2025

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of IN01, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account